HER2-low status and response to neoadjuvant chemotherapy in HER2 negative early breast cancer

被引：0
|
作者：
Luciana de Moura Leite
Marcelle Goldner Cesca
Monique Celeste Tavares
Debora Maciel Santana
Erick Figueiredo Saldanha
Paula Tavares Guimarães
Daniella Dias Silva Sá
Maria Fernanda Evangelista Simões
Rafael Lima Viana
Francisca Giselle Rocha
Simone Klog Loose
Sinara Figueiredo Silva
Rafaela Pirolli
Camilla Albina Zanco Fogassa
Bruna Raphaeli Silva Mattos
Fernando Augusto Batista Campos
Solange Moraes Sanches
Vladmir Cláudio Cordeiro de Lima
Noam Falbel Pondé
机构：
[1] A.C. Camargo Cancer Center,Department of Medical Oncology
来源：
Breast Cancer Research and Treatment | 2021年 / 190卷
关键词：
HER2; HER2-low breast cancer; Antibody–drug conjugates; Trastuzumab–deruxtecan; Trastuzumab–duocarmazine;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：155 / 163
页数：8
相关论文
共 50 条
  • [1] HER2-low status and response to neoadjuvant chemotherapy in HER2 negative early breast cancer
    de Moura Leite, Luciana
    Cesca, Marcelle Goldner
    Tavares, Monique Celeste
    Santana, Debora Maciel
    Saldanha, Erick Figueiredo
    Guimaraes, Paula Tavares
    Sa, Daniella Dias Silva
    Simoes, Maria Fernanda Evangelista
    Viana, Rafael Lima
    Rocha, Francisca Giselle
    Loose, Simone Klog
    Silva, Sinara Figueiredo
    Pirolli, Rafaela
    Fogassa, Camilla Albina Zanco
    Mattos, Bruna Raphaeli Silva
    Campos, Fernando Augusto Batista
    Sanches, Solange Moraes
    de Lima, Vladmir Claudio Cordeiro
    Ponde, Noam Falbel
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 190 (01) : 155 - 163
  • [2] Her2 low status and response to neoadjuvant chemotherapy in Her2 negative early breast cancer
    Mattos, Bruna RaphaeliSilva
    Cesca, Marcelle Goldner
    Leite, Luciana de Moura
    Tavares, Monique Celeste
    Silva, Sinara Figueiredo
    Pirolli, Rafaela
    Fogassa, Camilla AlbinaZanco
    Silva, Erick Figueiredo
    Rocha, Francisca Giselle
    Loose, Simone Klug
    Campos, Fernando AugustoBatista
    Sanches, Solange Moraes
    de Lima, Vladmir ClaudioCordeiro
    Ponde, Noam Falbel
    CANCER RESEARCH, 2021, 81 (04)
  • [3] The impact of HER2-low status on response to neoadjuvant chemotherapy in clinically HER2-negative breast cancer
    Wei Wang
    Tingting Zhu
    Hao Chen
    Yongzhong Yao
    Clinical and Translational Oncology, 2023, 25 : 1673 - 1681
  • [4] The impact of HER2-low status on response to neoadjuvant chemotherapy in clinically HER2-negative breast cancer
    Wang, Wei
    Zhu, Tingting
    Chen, Hao
    Yao, Yongzhong
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2023, 25 (06): : 1673 - 1681
  • [5] Impact of HER2 status (HER2-low versus HER2-0) on complete histologic response after neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC)
    Domergue, C.
    Martin, E.
    Lemarie, C.
    Jezequel, P.
    Frenel, J-S.
    Augereau, P.
    Campone, M.
    Patsouris, A.
    ANNALS OF ONCOLOGY, 2021, 32 : S428 - S429
  • [6] Clinical outcomes of neoadjuvant chemotherapy in HER2-low early breast cancer
    Gudelj, Dora
    Cular, Katarina
    Toula, Lea
    Krizic, Marija
    Popovic, Marina
    Plavetic, Natalija Dedic
    Kelecic, Ana
    Ivanac, Gordana
    Soce, Majana
    Gjergjaj, Iva Kukal
    Silovski, Tajana
    CANCER RESEARCH, 2024, 84 (09)
  • [7] HELENA: HER2-Low as a prEdictive factor of response to Neoadjuvant chemotherapy in eArly breast cancer
    François Cherifi
    Angélique Da Silva
    Alison Johnson
    Cécile Blanc-Fournier
    Olivia Abramovici
    Antonin Broyelle
    Christelle Levy
    Djelila Allouache
    Ioana Hrab
    Carine Segura
    Adeline Morel
    Maud Villemin
    Clémence Boscher
    Coraline Dubot-Poitelon
    Pauline Rottier
    Justine Lequesne
    George Emile
    BMC Cancer, 22
  • [8] HELENA: HER2-Low as a prEdictive factor of response to Neoadjuvant chemotherapy in eArly breast cancer
    Cherifi, Francois
    Da Silva, Angelique
    Johnson, Alison
    Blanc-Fournier, Cecile
    Abramovici, Olivia
    Broyelle, Antonin
    Levy, Christelle
    Allouache, Djelila
    Hrab, Ioana
    Segura, Carine
    Morel, Adeline
    Villemin, Maud
    Boscher, Clemence
    Dubot-Poitelon, Coraline
    Rottier, Pauline
    Lequesne, Justine
    Emile, George
    BMC CANCER, 2022, 22 (01)
  • [9] Impact of HER2-low status on axillary response and surgical management after neoadjuvant chemotherapy in early breast cancer
    da Silva, Leonardo Roberto
    Sartori, Guilherme
    Ramalho, Susana
    Reinert, Tomas
    Da Rosa, Mahira Lopes
    Tavares, Grazielle Morais
    Mantovani, Higor
    Vasconcelos, Vivian
    Cabello, Ana Elisa Ribeiro Da Silva
    Coelho, Guilherme
    Mandelli, Jovana
    Zaffaroni, Facundo
    Barrios, Carlos
    Graudenz, Marcia Silveira
    Cabello, Cesar
    CANCER RESEARCH, 2024, 84 (09)
  • [10] Prognostic implications of HER2 changes after neoadjuvant chemotherapy in patients with HER2-zero and HER2-low breast cancer
    Kang, S.
    Lee, S. H.
    Lee, H. J.
    Jeong, H.
    Jeong, J-H.
    Kim, J. E.
    Ahn, J-H.
    Jung, K. H.
    Kim, H. H.
    Lee, S.
    Lee, J.
    Kim, S-B.
    ANNALS OF ONCOLOGY, 2023, 34 : S305 - S305
12345